EUVIMEDEUVIMED entdecken
Crossref

G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study

Trang Thi Thu Tran, Ha Viet Le, Dang Huynh Hai Bui, Nga Huyen Do, Tien Dinh Vu, Nguyen Thi Lien Huong, Nguyen Thi Hong Hanh

Tạp chí Nghiên cứu Dược và Thông tin Thuốc · 17.11.2026 · 33

DOI: 10.59882/1859-364x/481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tạp chí Nghiên cứu Dược và Thông tin Thuốc, online erschienen am 17.11.2026. Verfasst von Trang Thi Thu Tran und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Granulocyte colony-stimulating factor (G-CSF) is recommended for preventing febrile neutropenia (FN) in patients receiving chemotherapy who are at increased risk. However, evidence regarding G-CSF selection and optimal filgrastim prophylaxis duration remains limited. This study aimed to assess the associations between different G-CSF prophylactic strategies and neutropenia-related outcomes among patients with breast cancer or non-Hodgkin lymphoma. A retrospective longitudinal observational study at K Hospital (January–March 2025), included patients receiving chemotherapy regimens with high or intermediate FN risk according to NCCN 2025. Neutropenia was graded using CTCAE v5.0. Associations were evaluated using propensity score overlap-weighted generalized estimating equations (GEE) in post hoc pairwise analyses. A total of 287 patients (1093 chemotherapy cycles) were included. Incidences of any-grade neutropenia, severe neutropenia, and neutropenia-related events were 18.7%, 3.6%, and 2.9%, respectively. In the pooled analysis involving both cancer types (691 cycles), filgrastim administered for 4–5 days was associated with higher odds of any-grade neutropenia than pegfilgrastim (33.8% vs. 4.7%; OR, 12.42; 95% CI, 5.43–28.40). Similar associations were observed in breast cancer-specific analyses for filgrastim administered for 1–3 days (680 cycles; OR, 9.23; 95% CI, 3.95–21.54) and 4–5 days among patients aged ≤65 years (462 cycles; OR, 12.50; 95% CI, 5.15–30.37). Estimates reflected distinct overlap populations, and reliable adjusted comparisons were not possible for non-Hodgkin lymphoma alone. G-CSF prophylactic strategies were associated with differences in documented any-grade neutropenia, but limited treatment overlap, potential residual confounding, and few clinically important events warrant cautious interpretation.

Zitieren

APA

Tran, T. T. T., Le, H. V., Bui, D. H. H., Do, N. H., Vu, T. D., Huong, N. T. L., & Hanh, N. T. H. (2026). G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study. Tạp chí Nghiên cứu Dược và Thông tin Thuốc, 33. https://doi.org/10.59882/1859-364x/481

Vancouver

Tran TTT, Le HV, Bui DHH, Do NH, Vu TD, Huong NTL, et al. G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study. Tạp chí Nghiên cứu Dược và Thông tin Thuốc. 2026;33. doi:10.59882/1859-364x/481

BibTeX
@article{Tran2026,
  author = {Tran, Trang Thi Thu and Le, Ha Viet and Bui, Dang Huynh Hai and Do, Nga Huyen and Vu, Tien Dinh and Huong, Nguyen Thi Lien and Hanh, Nguyen Thi Hong},
  title = {G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study},
  journal = {Tạp chí Nghiên cứu Dược và Thông tin Thuốc},
  year = {2026},
  volume = {33},
  doi = {10.59882/1859-364x/481}
}
Kostenlos starten →